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Abstract 
 
Aims:  The aim of the series of studies that comprise this thesis was to determine 
whether activation of peripheral N-Methyl-D-Aspartate receptors (NRs) in masticatory 
muscle causes pain through excitation of nociceptors and plays a mechanistic role in 
chronic masticatory muscle pain conditions. 
Methods: In vivo electrophysiology was performed to investigate how glutamate affects 
the activity of masticatory muscle nerve afferent fibers in Sprague Dawley rats. 
Immunohistochemical work was done to characterize the expression of various 
receptors by trigeminal ganglion neurons or nerve fibers that innervate the masticatory 
muscles in both rats and healthy humans.   Masseter muscle interstitial glutamate 
concentrations were measured by a glutamate biosensor and by microdialysis.  Healthy 
human subjects were recruited for studies which involved injection of glutamate alone, 
or with the NR antagonist ketamine, into the masticatory muscle to assess their effects 
on muscle pain.  Patients with myofascial temporomandibular disorders-related pain 
were recruited for studies to assess the analgesic effectiveness of ketamine, and to 
measure the interstitial concentration of glutamate in the masseter muscle. 
Results: Electrophysiological studies conducted in rats indicated that glutamate, in a 
concentration-dependent manner, can both excite and mechanically sensitize 
masticatory muscle nociceptors and that this occurs through activation of peripheral 
NRs.  Glutamate-evoked excitation of nociceptors was greater in female rats than in 
male rats; a difference mediated by estrogen levels.  Immunohistochemical studies 
found that NRs were expressed by about half of all masticatory muscle nociceptors, and 
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that their expression was greater in females than in males.  In humans, injection of 
glutamate into the masticatory muscles produced pain in a concentration related 
manner that was greater in women than in men.  Injection of glutamate also produced 
mechanical sensitization of the masticatory muscle which was similar in both sexes.  In 
rats, the non-steroidal anti-inflammatory drugs diclofenac and ketorolac, but not 
naproxen, were found to have NR antagonist properties when administered at 
concentrations achievable with topical creams or local injection.  Botulinum neurotoxin A 
was found to decrease nociceptor mechanical sensitivity by inhibition of release of 
glutamate in masticatory muscle.  In humans, pain and mechanical sensitization could 
be attenuated by local injection of ketamine, which indicates that it was mediated, in 
part, through activation of peripheral NRs.  Masseter muscle biopsies from healthy 
subjects identified NR expression in a subgroup of sensory nerve fibers.  In myofascial 
temporomandibular disorders patients, it was found that interstitial glutamate in the 
masseter muscle was elevated compared with healthy controls.  Treatment of 
myofascial TMD patients with an injection of ketamine into the most painful part of the 
masseter muscle, could decrease pain ratings in about half of women treated, but had 
no effect on men.   
Conclusions:  Elevated interstitial glutamate acts on peripheral NRs on craniofacial 
muscle nociceptors to produce pain and mechanical sensitization in humans.  In healthy 
humans and some myofascial temporomandibular disorders patients, the NR antagonist 
ketamine applied locally can attenuate pain and sensitivity that results from elevated 
glutamate concentrations in the muscle, which indicates that blockade of peripheral NRs 
is analgesic.  A number of other analgesic drugs that include diclofenac, ketorolac and 
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botulinum neurotoxin A, have mechanisms which involve NR antagonism or reduction of 
interstitial glutamate concentration in the muscle, respectively.  Modulation of 
glutamatergic tone in skeletal muscle may be a promising new approach for the 
treatment of myofascial pain. 
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Abstrakt 
Formål: Formålet med den række af studier, der ligger til grund for indeværende  
disputats, var at bestemme, om aktivering af perifere N-methyl-D-aspartat-receptorer 
(NRer) i tyggemuskelen forårsager smerte gennem excitation af nociceptorer og spiller 
en mekanistisk rolle ved kroniske smertetilstande i tyggeapparatet. 
Metoder: In vivo blev elektrofysiologi udført for at undersøge, hvordan glutamat påvirker 
aktiviteten i afferente nervefibre i tyggemusklen hos Sprague Dawley rotter. Der blev 
udført immunhistokemiske undersøgelser for at karakterisere manifestationen af 
forskellige receptorer i trigeminale ganglion-neuroner eller nervefibre, som innerverer 
tyggemuskler hos både rotter og raske mennesker. 
Interstitielle glutamat-koncentrationer i kæbemusklen blev målt ved hjælp af en 
glutamat-biosensor og mikrodialyse. Raske forsøgspersoner blev rekrutteret til forsøg 
med injektion af glutamat alene eller med NR antagonisten ketamin i tyggemusklen til 
vurdering af virkningen på muskelsmerter. Patienter med smerter, der var relateret til 
myofasciale temporomandibulære lidelser, blev rekrutteret til forsøg, der skulle vurdere 
den analgetiske virkning af ketamin og måle den interstitielle koncentration af glutamat i 
kæbemusklen. 
Resultater: Elektrofysiologiske undersøgelser på rotter viste, at glutamat på en 
koncentrationsafhængig måde både kan excitere og mekanisk sensibilisere 
tyggemusklens nociceptorer, og at dette sker ved aktivering af perifere NR'er. 
Glutamatfremkaldt excitation af nociceptorer var større hos hunrotter end hanrotter; 
hvilket er en forskel der er medieret af østrogen-niveauer. Immunhistokemiske 
undersøgelser viste, at NR'er blev udtrykt i omkring halvdelen af alle nociceptorer i 
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tyggemusklen, og at deres andel var større hos hunrotter end hos hanrotter. Hos 
mennesker fremkaldte injektioner af glutamat i tyggemusklerne smerter på en 
koncentrationsrelateret måde, der var højere hos kvinder end hos mænd. Injektion af 
glutamat producerede også mekanisk sensibilisering af tyggemusklen, hvor graden var 
ens hos begge køn. Hos rotter viste det sig, at de Non Steroidal Anti-Inflammatory Drug 
lægemidler diclofenac og ketorolac, men ikke naproxen, havde NR-antagonist-
egenskaber, når de blev indgivet i koncentrationer, som var opnåelige med topiske 
cremer eller lokal injektion. Botulinum neurotoksin A viste sig at reducere den mekanisk 
følsomhed af nociceptorer ved at hæmme frigivelsen af glutamat i tyggemusklen. Hos 
mennesker kan smerte og mekanisk sensibilisering dæmpes ved lokal injektion af 
ketamin, hvilket indikerer, at det delvist medieres gennem aktivering af perifere NRer. 
Kæbemuskel-biopsier fra raske forsøgspersoner identificerede NR-manifestation i en 
undergruppe af sensoriske nervefibre. Hos patienter med myofasciale 
temporomandibulære lidelser blev det konstateret, at interstitiel glutamat i kæbemusklen 
var forhøjet sammenlignet med raske kontrolpersoner. Behandling af patienter med 
myofasciale temporomandibulære lidelser ved hjælp af en injektion af ketamin i den 
mest smertefulde del af kæbemusklen viste sig at nedsætte smerte-scoren hos omkring 
halvdelen af kvinderne, mens injektionen ikke havde effekt på mænd.  
Konklusioner: Forhøjet interstitielt glutamat-niveau påvirker perifere NR'er i 
kraniofaciale muskelnociceptorer og forårsager smerte samt mekanisk sensibilisering 
hos mennesker. Hos raske personer og nogle patienter med myofasciale 
temporomandibulære lidelser kan NR-antagonisten ketamin indgivet lokalt dæmpe 
smerterne og den følsomhed, der skyldes forhøjede glutamat-koncentrationer i 
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musklen, hvilket indikerer, at blokaden af perifere NR'er er analgetisk. En række andre 
smertestillende lægemidler, der omfatter diclofenac, ketorolac og botulinum neurotoksin 
A, har mekanismer, der involverer henholdsvis NR-antagonisme eller reduktion af 
koncentrationen af interstitiel glutamat i musklen. Modulation af den glutamaterge tonus 
i skeletmuskulaturen kan være en lovende ny metode til behandling af myofasciale 
smerter.  
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Introduction 
Why glutamate? 
Inflammatory tissue injury results in swelling, redness and pain sensitivity.  This 
triad of symptoms, and in particular pain sensitivity, is due to the release of a complex 
cocktail of substances, collectively termed the “inflammatory soup” (14-16).  It had been 
well established prior to late 1990’s that several components of this soup, such as 
histamine, serotonin, prostaglandins, neuropeptides (e.g. substance P), protons and 
potassium, played important roles in the initiation and maintenance of pain sensitivity 
during inflammation (14-16).   The effectiveness of non-steroidal anti-inflammatory 
drugs (NSAIDs) and corticosteroids as analgesics had been shown to stem from their 
ability lower prostaglandin tissue concentration by actions through inhibition of 
cyclooxygenase, the key enzyme responsible for the synthesis of these compounds.  
This knowledge led to a great interest in identifying other potential targets for peripheral 
analgesics; an area of research that has remained active for many years now.  
Glutamate was subsequently identified as a component of the inflammatory soup in the 
late 1990’s (17).  This led to interest in glutamate and its receptors as potential 
analgesic targets.  
Glutamate activates receptors that can be divided into ionotropic and 
metabotropic subtypes (18-23). The former are mixed cation channels, which allow the 
passage of Na+, K+ and in some cases Ca++ across cell membranes to depolarize 
plasma membranes, while the latter are G-protein coupled and alter the intracellular 
concentrations of second messengers such as cylic-adenosine mono-phosphate, 
diacylglyerol and inositol triphosphate, that result in downstream effects on neuronal 
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excitability.  There are 3 ionotropic glutamate receptor subtypes which have been 
named for the agonist first describe to be selective for them; the N-methyl-d-aspartate 
(NMDA) receptor (NR) and two non-NMDA glutamate receptors (GluRs) the kainate 
receptor and the α-amino-3-hydroxy-5-methyl-5-isoxazolepropionate (AMPA) receptor  
(18-23).  There are 8 subtypes of metabotropic receptor (mGluR), which have been 
grouped into 3 families on the basis of the G-proteins and downstream signaling 
mechanisms they activate.  Group I mGluRs mediate their effects through Gq/G11 G-
proteins and stimulate the activity of phospholipase C.  Group II and Group III mGluRs 
are coupled to Gi/Go G-proteins and inhibit the activation of adenylate cyclase. 
The first indication for a nociceptive effect of activation of peripheral glutamate 
came from a study that found that application of either glutamate or kainate to the tail 
skin of neonatal rats evoked a putative nociceptive ventral root reflex (24, 25).  
Glutamate, but not kainate, appeared to evoke ventral root reflexes of a similar 
magnitude over repeated trials by activating a peripheral glutamate receptor.  Activation 
of the ventral root reflexes by application of kainate to the tail skin was competitively 
inhibited by the selective GluR antagonist 6,7-dinitroquinoxaline-2,3-dione (DNQX) 
applied to the tail, which suggested that it was mediated through activation of kainate 
receptors in the skin.  However, as this finding was made in neonatal rats, it was 
unclear whether the activation of these peripheral glutamate receptors was maintained 
into adulthood in rats. 
A few years later, it was reported that intraarticular injection of a NR antagonist 
appeared to attenuate nociceptive reflexes in adult rats (26).  In this model, mustard oil, 
which is inflammatory and nociceptive, is injected into the rat temporomandibular joint 
14 
 
and evokes a characteristic increase in the electromyographic activity of both the 
digastric ( jaw opener) and masseter ( jaw closer) muscles, bilaterally (26, 27).  Mustard 
oil evoked increases in reflex jaw muscle activity were attenuated by pre-injection of the 
non-competitive NR antagonist MK-801 into the temporomandibular joint. This result 
suggested that part of the nociceptive effect of mustard oil is mediated through the 
activation of peripheral NR. 
 Finally, a study in humans with the goal of increasing the effectiveness of local 
anesthetic wound infiltration under conditions of inflammation, such as occurs post-
surgery, suggested that peripheral NRs might play a role in nociception in humans (28).  
This study looked at the effectiveness of infiltration of the local anesthetic bupivacaine 
with and without the NR antagonist ketamine in 18 patients who had undergone hernia 
repair surgery.   The addition of ketamine to the bupivacaine infiltration increased the 
duration of anesthesia by 50-100%, and also resulted in a significant increase in patient 
tolerance to mechanical stimulation of the wound.  These results indicated that 
ketamine could act locally to increase the effectiveness of local anesthetics 
administered for pain relief post-surgery in humans.  This evidence in both rats and 
humans that peripheral glutamate receptors could play a role in inflammatory pain 
mechanisms led to interest in further dissecting the mechanisms whereby glutamate 
might contribute to peripheral pain mechanisms.  
 
Interstitial glutamate concentration and muscle pain. 
The concentration of glutamate in many peripheral tissues and in the blood is an 
order of magnitude greater than that found in the central nervous system.  In healthy 
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men and women, normal blood glutamate concentrations range from 20-60 µM, and in 
both men and women glutamate concentration in the blood appears to increase with 
age (29).  Glutamate is actively transported from the blood into skeletal muscle, and the 
rate at which it is taken up is proportional to its concentration in the blood (30).  This 
means that under conditions where glutamate concentration is elevated, such as 
consumption of a high glutamate content meal, skeletal muscle acts to rapidly remove 
excess glutamate from the blood and store it (30, 31).  In addition, skeletal muscle 
contains a large storage of glutamine, which can be converted to glutamate by the 
enzyme glutaminase.  There is also evidence that glutamate is transported 
anterogradely to peripheral terminals of sensory afferent fibers that innervate skeletal 
muscle, and is likely released from them (32).  As a result, interstitial concentrations of 
glutamate in skeletal muscle approximate or even exceed those in the blood.     
In microdialysis studies where relative recovery rate of glutamate has been 
determined using 14C labelled glutamate, mean interstitial glutamate concentrations in 
skeletal muscle ranged from 15-60 µM (33, 34).  This means that peripheral endings of 
sensory nerve fibers which innervate skeletal muscle are also exposed to resting 
glutamate concentrations 10-50 times higher than their endings in the central nervous 
system.  This may explain the association that has been made between elevated 
interstitial concentration of glutamate and muscle pain in certain chronic 
musculoskeletal pain conditions, such as tendonitis and polymyalgia rheumatica (34-
40).   
Interstitial glutamate concentrations have been reported to increase dramatically 
in several non-inflammatory pain conditions involving skeletal muscle and/or tendons 
16 
 
(41-43).  In tendons, such as the extensor carpi radialis brevis tendon of patients with 
tennis elbow and the patellar tendon of patients with “jumpers knee”, glutamate 
concentrations of greater than 200 μM have been found (41-44). In skeletal muscle it 
has been reported that baseline pain pressure thresholds showed a significant negative 
correlation with muscle glutamate concentration in women with chronic work-related 
trapezius myalgia (43).  During a low force exercise that resulted in muscle pain, 
glutamate concentrations were positively correlated to the magnitude of muscle pain 
reported by both healthy subjects and those with chronic trapezius myalgia (43).  In 
other studies, no differences in interstitial glutamate concentrations in the trapezius 
muscle between healthy controls and pain patients have been identified (45, 46).   
Glutamate as a peripheral neuromodulator 
Cutaneous:  Much of the initial research to evaluate how glutamate and its receptors 
contribute to peripheral pain processing was done in cutaneous tissues. Behavioral 
investigations in adult rats found that subcutaneously-administered glutamate activates 
all three subtypes of inotropic glutamate receptors as well as metabotropic glutamate 
receptors.  Subcutaneous or intradermal injection of glutamate or selective agonists 
(NMDA, AMPA or kainate) as well as Group I mGluR agonists into the rat paw results in 
sensitization of the skin to noxious mechanical and/or thermal stimulation (47-53) and 
nocifensive (pain-related) behaviors, such as paw licking (54, 55).  These findings 
indicate that there are functional inotropic and metabotropic receptors in cutaneous 
tissue and that their activation is noxious.  
In the skin, glutamate appears to activate both nociceptive and non-nociceptive 
afferent fibers.    Subcutaneous injection of glutamate activates roughly 80% of 
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mechanoreceptive C, Aδ and Aβ fibers that innervate the skin of the rat’s back (56, 57).  
In the rat paw, there has been some evidence that glutamate may selectively sensitize 
putatively nociceptive Aδ and C fibers to mechanical and thermal stimuli (58).  
Glutamate also excites slowly-conducting corneal afferent fibers in vivo, whose function 
is principally related to nociception (59).     However, the response of slowly adapting 
type 1 mechanoreceptive afferents of rat whiskers to sustained mechanical stimulation 
is attenuated by NR antagonists, which suggests that glutamate excites both fast and 
slowly conducting cutaneous fibers (60, 61).    Subcutaneous injection of glutamate 
induced a significant mechanical sensitization of facial skin afferent fibers in the rat (62).  
Mechanical sensitization of facial cutaneous afferent fibers was attenuated by an NR 
antagonist (62). Taken together, these findings suggest that elevated levels of 
glutamate in the skin decrease the activation threshold for both low threshold 
mechanoreceptive afferent fibers as well as nociceptors.   
Translational studies have been conducted to determine the ability of glutamate 
to cause pain in humans. Subcutaneous injection of glutamate into the forehead 
induces pain, mechanical sensitization and vasomotor responses in healthy men and 
women (63).   Pain intensity was concentration-dependent, and greater pain responses 
were reported by women than men. Concentration-dependent local vasomotor 
responses, which are thought to result from neurogenic inflammation, were also found 
following the subcutaneous injection of glutamate, but there was no sex difference in 
this effect. 
Visceral:  Almost all information about the role of peripheral glutamate receptors in 
visceral pain has been derived from studies which have examined the gastrointestinal 
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tract.  Vagal afferent fibers which innervate the duodenum and stomach have their cell 
bodies in the nodose ganglion, while colorectal afferent fibers of the splanchnic and 
pelvic nerves have their cell bodies in the dorsal root ganglion.  A number of studies 
have demonstrated that nodose ganglion and dorsal root neurons express most if not all 
glutamate receptor subtypes (64-69).  The ongoing discharge and mechanically evoked 
responses of vagal afferent fibers is enhanced by glutamate receptor agonists and 
decreased by their antagonists, which suggests that inotopic glutamate receptor 
activation, particularly NR activation, modulates vagal afferent sensitivity (64, 65, 69).  
The mechanical responsiveness of colorectal afferent fibers of the pelvic nerve can also 
be reduced by NR receptor antagonists, and this effect is mediated principally through 
activation of the NR2B subtype (68-71).  These findings indicate that visceral afferent 
fiber excitability can be modulated by peripheral glutamate receptor activation.  Studies 
to determine whether peripheral glutamate levels contribute to visceral pain in humans 
have not been undertaken. 
Musculoskeletal: Functional inotropic glutamate receptors have been found in the 
temporomandibular (jaw) joint, where intraarticular injection of glutamate evoked a 
reflex jaw muscle response that could mimicked by injection of NMDA, AMPA or kainate 
and attenuated by co-injection of AP5 and CNQX (72).  Behavioral evidence for the 
involvement of mGluRs in muscle pain is derived from experiments where injection of 
glutamate or a group I mGluR agonist into the masseter muscle evoked nocifensive 
behavior and induced mechanical sensitization (73, 74).  These findings indicate that 
there are functional peripheral inotropic and metabotropic receptors within both joints 
and muscles. 
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 Elevation of glutamate concentration in joints and muscles excites slowly 
conducting (Aδ and C) afferent fibers with high mechanical thresholds that likely serve 
nociceptive roles as well as Aβ afferent fibers with lower mechanical thresholds that 
may be involved in proprioception (Figure 9-2) (75-77).  The majority of the peripheral 
NRs expressed by muscle afferent fibers contain the NR2B subunit with far fewer that 
express the NR2A subunit and NMDA-evoked muscle afferent discharge is significantly 
attenuated by the NR2B selective antagonist ifenprodil (76, 78-82).  Overall, NRs are 
expressed by more than 50% of the afferent fibers that the masticatory muscles, which 
implies that they must play an important role in modulating the function of these afferent 
fibers (7, 13, 83). 
Injection of glutamate into neck and masticatory muscles reliably evokes pain 
and induces a period of mechanical sensitization in healthy human subjects (84-87).  
Both glutamate-evoked pain and glutamate-induced mechanical sensitization are 
reduced by local administration of the NR antagonist ketamine (5, 88).  Thus, as in the 
skin, results from animal studies appear to be translatable into humans. 
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Aim and Hypotheses 
The overall aim of the series of studies that comprise this thesis was to 
determine whether activation of peripheral NRs in masticatory muscle tissue causes 
pain through excitation of nociceptors and plays a mechanistic role in chronic 
masticatory muscle pain conditions. 
Hypothesis 1:  Elevation of peripheral glutamate concentration will excite and sensitize 
nociceptors through activation of NRs. 
Hypothesis 2:  Afferent fibers that innervate the masticatory muscles express NRs. 
Hypothesis 3:  The response to glutamate in females will be greater than in males, and 
this difference will be due, in part, to estrogen levels. 
Hypothesis 4:  Activation of peripheral NRs in human muscle by intramuscular injection 
of glutamate will cause pain and induce mechanical sensitization that will be greater in 
women than in men. 
Hypothesis 5:  Glutamate levels will be elevated in the muscles of myofascial TMD 
patients and local administration of a NR antagonist will decrease pain in this condition. 
Hypothesis 6:  Co-injection of NR antagonists with local anesthetics into inflamed 
tissue will increase block duration compared to injection of local anesthetic alone. 
Hypothesis 7:  Botulinum neurotoxin A increases the mechanical activation threshold 
of masticatory muscle afferents by decreasing interstitial glutamate concentration. 
Hypothesis 8:  The non-steroidal anti-inflammatory drugs diclofenac and ketorolac, in 
addition to blocking prostaglandin synthesis, will also block peripheral NRs.
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Methodologies Employed 
 
Electrophysiology:   
In vivo electrophysiology was performed in studies (i-iii, v-vii, ix, x, xii & xiii) where the 
activity of masticatory muscle afferent fibers was investigated.  All in vivo 
electrophysiology experiments used Sprague Dawley rats.  These animals were 
prepared for acute recording of trigeminal primary afferent activity under isoflurane 
anesthesia. The basic experimental recording setup for in vivo recording of trigeminal 
nerve is illustrated in Figure 1 (ii, (2)). The recording electrode was inserted with a 
microdrive into the trigeminal ganglion, where the cell bodies of slowly conducting 
afferent fibers that innervate the masticatory muscles are located (2, 89).  The output of 
the recording electrode was routed through an amplifier and analog-to-digital board 
(CED 1401, Cambridge Electronic Devices, UK) into a computer equipped with Spike 2.  
The output of the electronic Von Frey hair was connected to the computer to permit 
simultaneous recording of action potential discharge and mechanical stimulus intensity, 
as shown in the simulated computer monitor below.  Anatomical evidence indicates that 
the vast majority of slowly conducting (Aδ and C) afferent fibers project by way of the 
trigeminal ganglion to the trigeminal subnucleus caudalis (90).  To help ensure that 
these afferent fibers were recorded from the subnucleus caudalis, a brainstem 
stimulating electrode was placed in contact with the caudal brainstem and was used to 
activate the central termination of muscle nociceptors in the trigeminal subnucleus 
caudalis.  Except in study ii (2), all afferent fibers examined had projections to this part 
of the trigeminal sensory nuclear complex.    In recent experiments, a Hamilton syringe  
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Figure 1:  An illustration of the in vivo electrophysiology recording set up is shown. 
 
has been inserted into the caudal trigeminal ganglion and used to micro-inject solutions 
containing neurotransmitters and/or their antagonists. 
 
Immunohistochemistry: 
In certain experiments (vii, x, xiii), immunohistochemical work was done to 
characterize the expression of various receptors by trigeminal ganglion neurons or 
nerve fibers that innervate the masticatory muscles.  To identify ganglion neurons that 
innervated the masticatory muscles, a fluorescent tracer dye (fast blue or rhodamine) 
was injected into the muscle of interest.  To identify nerve fibers in muscle tissue, 
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primary antibodies against the pan axonal marker PGP 9.5 were used.  Seven days 
after injection, rats were euthanized and then perfused with paraformaldehyde.  
Trigeminal ganglia as well as muscle tissue in some cases, were removed and 
cut into sections (10-40 µm) with a vibratome or cryotome.  Primary antibodies were 
obtained from commercial sources (e.g. Sigma, AbCam). Sections were treated with 5% 
normal goat serum (NGS) in phosphate-buffered saline for 1 h followed by overnight 
incubation with appropriate primary antibodies in phosphate-buffered saline containing 
1% normal goat serum. The next morning sections were washed several times with 
phosphate-buffered saline and then incubated for 1 h at room temperature in the dark in 
the presence of fluorescent-conjugated secondary antibodies for antibody localization. 
After several washes in buffer, sections were mounted on slides with coverslips and 
imaged with a Leica fluorescence microscope, or in later studies, a Leica TCS SPE high 
resolution spectral confocal microscope.  
 
Tissue Glutamate Concentration 
Masseter muscle interstitial glutamate concentrations were measured by a 
glutamate biosensor and by microdialysis.  A glutamate biosensor from Pinnacle 
Technology (USA) was calibrated in vitro according to the manufacturer’s instructions 
and has the advantage of excellent time resolution (4 hz sampling speed) and real time 
visualization of glutamate concentration.  The glutamate biosensor is a platinum–iridium 
electrode coated with a layer of a passive-selective membrane (Nafion and Cellulose 
Acetate) followed by a layer of the enzyme glutamate oxidase, which catalyzes the 
conversion of glutamate and oxygen to α-ketoglutaric acid and hydrogen peroxide.  The 
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hydrogen peroxide produced is detected when it diffuses through the passive-selective 
membrane and is oxidized at the surface of the platinum–iridium electrode (applied 
potential, 600 mV). The passive-selective membrane limits interference from other 
substances present in muscle tissue which could be oxidized at the surface of the 
platinum–iridium electrode at a similar applied potential.   The glutamate biosensor was 
inserted into the masseter muscle with a catheter and used to record glutamate 
concentrations for periods exceeding 3 hours. 
Microdialysis was performed in both humans and animals by inserting a 
commercially acquired microdialysis probe with a membrane exclusion of molecules 
greater than 10 kDaltons.  In human subjects, the skin over the masseter muscle was 
anesthetized prior to insertion of the probe (by means of a needle catheter) with EMLA 
cream, a local anesthetic.  The probe was connected to a microinfusion pump and 
perfused at 2 µl/minute with dialysate solution (sterile, phosphate buffered saline).   
Collected dialysate was analyzed either by a commercial kit (Amplex Red Glutamic 
Acid/Glutamic Oxidase Assay Kit, Molecular Probes) or by high performance liquid 
chromatography (6, 11). 
 
 
 
 
Figure 2:  The pictures show the microdialysis pump (on the left) and insertion of a 
microdialysis probe into the masseter muscle of a human subject (on the right). 
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Human Experimental Pain Studies 
Healthy subjects without signs or symptoms of TMD (Dworkin and LeResche, 1992) 
were recruited for the various human experimental studies.  The local ethics committee 
in Denmark (Counties of Nordjylland and Viborg) approved the study protocol and all 
individuals gave their informed consent in accordance with the Helsinki Declaration. 
Intramuscular injections into the masseter and or temporalis muscle were made 
manually with thin gauge (27-30) hypodermic needles and disposable syringes.   All 
sterile solutions injected were prepared by a hospital pharmacy (glutamate, hypertonic 
saline) or purchased directly from the manufacturer in injectable form (ketamine).  
Subjects continuously rated their pain intensity evoked by intramuscular injections on an 
electronic 10-cm visual analogue scale. The lower endpoint of the VAS was labeled ‘no 
pain at all’ and the upper endpoint labeled ‘the most pain imaginable. 
A pressure algometer (Somedic, Sweden) with a probe diameter of 1 cm was used 
to assess mechanical sensitivity of the masticatory muscles. The pressure pain 
threshold (PPT) was defined as the amount of pressure (kPa) which the subjects first 
perceived to be painful. The pressure pain tolerance (PPTol) was defined as the 
maximum amount of pressure subjects could tolerate.  Subjects pushed a button to stop 
the pressure stimulation when the threshold or tolerance was reached.  PPT and PPTol 
were determined by applying the algometer at a constant application rate of 30 kPa/s. 
Subjects were asked to keep their jaw at rest and not to clench their teeth during testing 
because contraction of the jaw closing muscles may influence the determination of 
mechanical sensitivity.  
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Microbiopsies 
Microbiopsies were obtained from healthy human subjects through the use of a 
disposable biopsy instrument (BARD Norden, Helsingborg, Sweden).  The biopsy 
instrument was inserted through the skin surface overlaying the bulky part of the 
superficial masseter muscle under local anesthesia (5% lidocaine).  The biopsy 
instrument was used to collect a sample of muscle tissue with a size of approximately 
~0.1 cm3. The muscle section was removed from the biopsy instrument using a sterile 
probe, and the biopsy instrument was rinsed with isotonic saline. This procedure was 
repeated two more times, which resulted in a total of three micro-biopsies samples from 
the masseter muscle. 
 
Clinical Studies 
 Patients with myofascial temporomandibular disorders related pain were 
recruited.  All patients were diagnosed with the Research Diagnostic Criteria for 
Temporomandibular Disorders (RDC/TMD) by a qualified dental specialist.  All patients 
were required to sign an informed consent form and were treated in accordance with the 
Helsinki Declaration.  Patients were required to have spontaneous (ongoing) pain of at 
least 2/10 on the numeric rating scale as well as pain on palpation of the masseter 
muscle.  Patients were excluded if they were pregnant, had other musculoskeletal pain 
disorders (fibromyalgia, arthritis, etc.), serious systemic diseases (e.g. malignancy), or 
were receiving medications for pain or mental health conditions.   
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Results and Discussion 
Masticatory Muscle Nociceptor Activity is Modulated by Glutamate Concentration 
Initial animal work to examine whether glutamate is a peripherally acting algogen 
involved injection of glutamate into various tissues and assessment of behavioral 
response to these injections in animals (27, 91, 92).   These studies determined that 
injection of low concentrations of glutamate (≤ 1mM), did not evoke nocifensive 
behavior but did induce a period of localized mechanical sensitization.  Most of this work 
was done with subcutaneous injections, often into the rat paw (92).  Injection of higher 
concentrations of glutamate (> 50 mM) produced nocifensive behavior or evoked 
nociceptive reflexes in a concentration related manner, when injected either 
subcutaneously or into deep tissues (27, 91).   It was also found that both NRs and non- 
NRs were involved in sensitization and nocifensive behaviors induced by injection of 
glutamate (27, 91, 92).  However, one criticism of this work was that none of these 
studies could directly demonstrate that the injected glutamate was having an effect on 
nociceptors. 
To address this concern, I developed a method for recording the activity of 
masticatory muscle nociceptors in vivo (Figure 1), and examined the effect of glutamate 
on nociceptor excitability (1, 2).  Injection of glutamate into the masseter muscle evoked 
action potential discharge in a concentration-related manner from both slowly 
conducting (Aδ and C) afferent fibers as well as Aβ fibers (Figure 3A) (i) (1).  Injection of 
a high concentration of glutamate (1000 mM) into the masseter muscle, also 
significantly decreased the mechanical threshold of afferent fibers that innervate this 
muscle (ii) (2) (Figure 3B).  Glutamate-evoked afferent discharges were very sensitive 
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to, and discharge could be almost completely prevented by, both competitive (5-amino-
phosphonovalerate (APV)) and non-competitive (ketamine) NR antagonists (v) (5) 
(Figure 3C).  Glutamate-induced mechanical sensitization was sensitive to block of NRs 
and non-NR s (2, 10).  While these findings confirmed that peripherally administered 
glutamate could activate and sensitize muscle nociceptors, concern that the 
concentrations used were far outside the normal physiological range of glutamate in 
tissues led to renewed skepticism as to the role of glutamate in peripheral muscle pain 
mechanisms. 
To determine whether more physiological changes in glutamate concentration 
would produce similar effects on muscle nociceptors, a series of experiments was 
conducted to measure the interstitial concentration of glutamate in the masseter muscle 
as well as to monitor the activity of muscle nociceptors after systemic administration of 
monosodium glutamate (MSG) (vi) (6).  A dose of 50 mg/kg MSG was administered 
intravenously to the rats, since this dose was considered roughly equivalent to oral 
intake of 150 mg/kg of MSG; a dose associated with headache, facial flushing and 
discomfort by some humans (2).    In rats, a dose of 50 mg/kg MSG given intravenously 
raised interstitial concentrations of glutamate in the masseter muscle from 25 to 65 μM 
(vi) (6) (Figure 4A).  This degree of elevation of interstitial glutamate in the muscle was 
associated with significant mechanical sensitization of nociceptors that was mediated 
through NR activation (vi) (6).  Mechanical sensitization induced by intravenously 
administered glutamate lasted for 15 minutes, and the magnitude of the sensitization 
appeared related to the concentration of glutamate in the muscle (Figure 4B).  Only one 
afferent fiber responded to glutamate with action potential discharges.   
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Figure 3: A, Glutamate (500 mM) evoked the largest afferent discharge in C fibers (1).  
B, Injection of 1 M glutamate induced a prolonged mechanical sensitization of masseter 
muscle afferent fibers (2).  C, Concentration-related inhibition of glutamate-evoked 
afferent discharge by the NR antagonists APV and ketamine (5). 
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Figure 4: A, Intravenous injection of 50 mg/kg of MSG increased the interstitial 
concentration of glutamate in the rat masseter muscle and B, caused a 25% decrease 
in masseter afferent fiber mechanical threshold which returned to baseline after 10 min 
(6). 
 
The high basal interstitial concentration of glutamate in the masseter muscle (~ 25 µM) 
in vivo may, in part, explain why higher concentrations of exogenously applied 
glutamate appear to be required to excite and sensitize afferent fibers in muscle. 
These studies also indicated that the excitatory effect of elevated interstitial 
glutamate concentrations on muscle afferent fibers is mediated primarily through 
activation of peripheral NRs, since glutamate-evoked discharge and mechanical 
sensitization of muscle afferent fibers could be completely attenuated by local or 
systemic administration of NR antagonists (2, 5, 6, 10) (Figure 3C).   
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Muscle Nociceptors Express NRs of the NR2B Subtype 
Injection of glutamate into the rat masseter muscle does not evoke discharge in 
all afferent fibers.  To determine how common the expression of the NR is in muscle 
afferent fibers, and whether certain NR subtypes are more common than others, 
immunohistochemical examination of trigeminal ganglion neurons that innervate the 
masseter muscle was carried out.  Trigeminal ganglion neurons that innervate the 
masticatory muscle have a diameter between 3-70 µm (7, 83).  Roughly 10- 20% of 
trigeminal ganglion neurons that project to the masseter muscle expressed the NR2A 
subunit, while about 40-50% of ganglion neurons expressed the NR2B subunit (vii, xiii) 
(7, 13, 83).  In the masseter muscle, PGP 9.5 was used to identify nerve axons and the 
expression of the neuropeptides CGRP or substance P to identify sensory afferent 
fibers that innervate the muscle (x) (10).   In the muscle, it was found that ~ 50% of 
sensory afferent fibers expressed the NR2B subunit, consistent with its expression by 
trigeminal ganglion neurons that innervate the masseter muscle (x) (10). 
Injection of NMDA into the masseter muscle also evokes afferent discharge and 
induces a period of afferent mechanical sensitization.  Ifenprodil is a non-competitive 
antagonist selective for NR2B subunit containing NRs.  It was found that local 
administration of ifenprodil could significantly attenuate, but did not completely block 
NMDA-evoked afferent discharge (vii) (7) (Figure 5).  This suggests that in many 
nociceptors, it is activation of NR2B subunit containing NRs that mediates the effects of 
glutamate.  Thus, the majority of the peripheral NRs expressed by masseter muscle 
afferent fibers contain the NR2B subunit with fewer that express the NR2A subunit.   
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Figure 5:  The images show two trigeminal ganglion neurons labeled by injection of fast 
blue dye into the temporalis muscle (arrows).  The larger of the two neurons expressed 
the NR2B subunit (magnified images at bottom).  The bar chart shows how ifenprodil, 
an NR2B selective NR antagonist, significantly attenuated afferent discharge evoked by 
NMDA.  
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Afferent fibers that innervate the viscera also appear to express mostly NR2B subunit 
containing NRs, which is consistent with findings in the muscle (93).  These findings 
suggest that NR2B selective antagonists could be effective in attenuating pain and 
sensitivity produced by elevated tissue concentrations of glutamate. 
 
Response to glutamate is sexually dimorphic 
Masticatory muscle pain and tenderness is one of the most common symptoms 
reported by sufferers of chronic craniofacial pain conditions, such as 
temporomandibular disorders and migraine headache (94).  Interestingly, about twice as 
many women as men suffer from these pain conditions, although the reasons for this 
disparity remain enigmatic (94).  Although at the time most researchers were only using 
male rats in pain studies, both male and female rats were used to examine the effect of 
elevated glutamate levels on nociceptive input from the masticatory muscles.   Injection 
of glutamate or NMDA into the masseter muscle evoked significantly greater afferent 
discharge in females than in males (i, vii) (1, 7).  However, afferent discharges evoked 
by injection of glutamate or NMDA into the temporalis muscle were similar in male and 
female rats (89).   There was no sex-related difference in glutamate-induced mechanical 
sensitization (ii) (2).   
It had been found that female rats have greater nociceptive reflex responses in 
the jaw muscles to injection of glutamate into the temporomandibular joint than male 
rats (95).  The increased reflex jaw muscle response of female rats to glutamate was 
eliminated by ovariectomy, but restored when ovariectomized female rats were treated 
with estrogen, but not progesterone (95).  Nociceptor discharge was also greater in 
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females than in males, when either glutamate or NMDA was injected into the masseter 
muscle (Figure 6) (i, ii, vii) (1, 2, 7).   In ovariectomized female rats, pre-treatment with 
estrogen to achieve levels similar to those seen at ovulation or during pregnancy, also 
significantly increased NMDA-evoked masseter muscle afferent discharges (vii) (7).  
This effect was associated with an increase in the expression of NR2B subunit 
containing NRs by trigeminal ganglion neurons that innervate the masseter muscle in 
female rats treated with estrogen (vii) (7).  Subsequently, it has been found that both 
estrogen α and β receptors are expressed by trigeminal ganglion neurons in female 
rats, and that more that 80% of NR2B expression masticatory muscle ganglion neurons 
also express estrogen receptors (83).  This suggests that expression of NRs by 
masticatory muscle afferents is directly controlled by estrogen levels in female rats, and 
may explain why glutamate-evoked afferent discharge is sexually dimorphic. 
 
Figure 6:  The semi-log line and scatter plot 
illustrates the concentration-response 
relationship for NMDA-evoked masseter 
nociceptor discharge in male and female 
rats.  Nociceptors in male rats were less 
sensitive to NMDA than those in female rats.  
Data points indicate median and interquartile 
range.  *p<0.05, Mann Whitney test. 
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Elevation of glutamate in the human masseter muscle is painful and induces 
mechanical sensitization 
To determine whether results obtained in rats were translatable into humans, 
human experimental pain studies where glutamate was injected into the masseter 
muscle of healthy human volunteers have been conducted (i, iv, v).  In healthy subjects, 
injection of glutamate [100-1000 mM, 0.2 ml] into the masseter or temporalis muscles 
produces short-lasting muscle pain with a peak intensity of around 4-6/10 on the 
numeric rating scale, and a duration of about 5-10 minutes (i, iv, v) (1, 4, 5, 84, 86, 96-
98) (Figure 7).   Assessment of pain pressure threshold over the site of injection in the 
muscle revealed a significant decrease could be induced by high concentration (1 M) 
glutamate (4, 88).  This glutamate-induced mechanical sensitization began within 15 
minutes of injection and lasted for 90 minutes or longer in some individuals (iv) (4, 88).   
It was further noted that injection of glutamate (500 or 1000 mM, 0.2 ml) into the 
masseter muscle evoked significantly greater pain responses in women than in men (i, 
iv) (1, 4, 84).  Glutamate-induced mechanical sensitization was similar in men and 
women (iv) (4). 
Glutamate-evoked pain and glutamate-induced mechanical sensitization were 
attenuated by co-injection of the NR antagonist ketamine (10 mM) in men (v) (5, 88) 
(Figure 8).  Interestingly, this same concentration of ketamine was found to be 
ineffective in attenuating glutamate evoked pain in a subsequent study in women (97).  
A more recent study found that a higher concentration of ketamine (20 mM) was needed 
to reduce glutamate-evoked muscle pain in healthy women (84).   
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Figure 7:  The concentration response relationship for glutamate-evoked masseter 
muscle pain in healthy men and women is illustrated.  Injection of glutamate into the 
masseter muscle produced significantly greater pain and pain area drawings in women 
than in men. 
 
Masseter muscle biopsies from healthy men and women were examined for 
expression of NR2B subunits and substance P by nerve fibers (xiii).  In healthy men 
and women, comparable basal expression levels of NR2B and SP were found in 
PGP9.5 identified nerve fibers (13). There was a tendency towards higher expression of 
NR2B by putative sensory nerve fibers (identified by their expression of substance P 
receptors) in women than in men (13). 
These findings indicate that exogenous increases in masticatory muscle 
glutamate result in pain and mechanical sensitization, similar to that seen in rats.  In 
humans, both glutamate evoked pain and mechanical sensitization could be attenuated 
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by ketamine, and NRs have been shown to be expressed by putative sensory fibers that 
innervate the human masseter muscle.  Taken together, these findings are consistent 
with the idea that peripheral NR s are activated by elevated glutamate concentrations in 
human masticatory muscle to cause pain and mechanical sensitization. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8:  The drawing shows mean electronically recorded visual analogue scale 
(VAS) responses from 14 healthy men given two injections of glutamate (G) or 
hypertonic saline with and without the NR antagonist ketamine (K).  Injection of either G 
or S evoked reproducible pain responses.  K significantly decreased responses to G but 
not S. 
10 min
0
1
2
3
4
5
0
1
2
3
4
5
G
1.0 M
G
1.0 M
G
1.0 M
G 1.0 M &
K 10 mM
S
1.0 M
S 
1.0 M
S 
1.0 M
S 1.0 M &
K 10 mM
VA
S 
Sc
or
e
Control Ketamine
38 
 
Interactions between glutamate receptors and analgesic drugs 
Infiltration of local anesthetics into inflamed tissue can result in a failed local 
anesthetic block.  The reasons for this failure are complex, and may involve 
sensitization of afferent fibers as well as pharmacokinetic factors, which include tissue 
edema and increased blood flow.  Glutamate is found in increased concentrations in 
inflamed tissues and, as has been discussed above, could contribute to sensitization of 
nociceptive afferent fibers that is characteristic of inflammation.  A study was 
undertaken to determine if elevated tissue glutamate concentrations can shorten the 
duration of local anesthesia induced by injection of lidocaine into the rat masseter 
muscle (iii).   Pre-injection of glutamate (1000 mM) was found to significantly decrease 
the mechanical threshold of masseter muscle nociceptors and shorten the duration of 
their block by lidocaine compared to isotonic saline (3).  Glutamate-induced 
sensitization and glutamate-related shortening of the duration of lidocaine block were 
significantly attenuated when the broad-spectrum excitatory amino acid receptor 
antagonist kynurenate was co-injected with glutamate (3). Thus, activation of NRs and 
non-NRs on masseter nociceptors was contributing to the ability of high concentrations 
of glutamate to shorten lidocaine anesthetic blocks.  Hypertonic dextrose, which has 
approximately the same osmotic strength as 1,000 mM glutamate, had no effect on the 
nociceptor mechanical threshold but did significantly shorten the duration of lidocaine 
block compared with isotonic saline. The duration of lidocaine block after glutamate 
was, however, significantly shorter than after hypertonic dextrose.  These findings 
indicate that under conditions, such as inflammation, which lead to tissue 
concentrations of glutamate becoming sufficiently elevated to sensitize nociceptors, 
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local anesthetic blocks will be shortened.  It may be possible to avoid this effect by 
administering the local anesthetic with a glutamate receptor antagonist, such as 
kynurenate or ketamine. 
 Botulinum neurotoxin A (BoNTA) is used to decrease the frequency of migraine 
headaches.   BoNTA is injected into several craniofacial muscles that include the 
temporalis muscle about every 3 months.  It remains unclear how BoNTA decreases the 
frequency of migraine headaches, however, there is evidence that BoNTA may be 
effective in other pain conditions, such as neuropathic pain, which suggests that it is 
capable of exerting a local analgesic action.  To investigate this idea, the effect of 
BoNTA on the mechanical and chemical responsiveness of individual temporalis muscle 
nociceptors and muscle neurogenic vasodilation was undertaken in female rats (x) (10).  
Three hours after injection of BoNTA into the temporalis muscle, there was a significant 
increase in the mechanical threshold of muscle nociceptors.  BoNTA treatment also 
prevented injection of glutamate from inducing mechanical sensitization or neurogenic 
vasodilation.  These effects of BoNTA did not appear due to muscle paralysis, since 
systemic administration of the neuromuscular blocker pancuronium had no effect on 
nociceptor mechanical threshold or on the ability of glutamate to induce mechanical 
sensitization or neurogenic vasodilation.  Measurement of interstitial glutamate 
concentration with a glutamate biosensor indicated that BoNTA significantly reduced 
glutamate concentrations in the temporalis muscle over the same time frame as 
mechanical sensitivity changes (10).   These findings suggest that injection of BoNTA 
into craniofacial muscles decreases the mechanical sensitivity of temporalis muscle 
nociceptors through inhibition of glutamate release. 
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 Topical non-steroidal anti-inflammatory drugs (NSAIDs) containing diclofenac are 
not only effective analgesics in inflammatory pain conditions like arthritis, but also 
appear to be useful in reducing muscle pain in conditions that are not associated with 
frank inflammation, such as myofascial temporomandibular disorders (94).  The 
analgesic effect of NSAIDs is thought to be due to their ability to inhibit prostaglandin 
synthesis, which is significantly increased by tissue inflammation.  Topical application of 
NSAIDs results in local tissue concentrations that greatly exceed those achieved by 
systemic administration of these drugs.  This may mean that additional mechanisms 
contribute to their analgesic actions.  Indeed, the analgesic effect of topical diclofenac in 
non-inflammatory pain conditions, such as temporomandibular disorders (94), where 
inflammatory mediators would not be expected to contribute as greatly to pain, suggests 
that other mechanisms contribute to the analgesic efficacy of this NSAID when used 
topically. 
  Human experimental pain research suggests that elevation of serotonin (5-HT) 
and/or glutamate concentrations in skeletal muscle tissue is associated with muscle 
pain and sensitization (11, 99).  An in vivo study in anesthetized rats was conducted to 
determine if diclofenac, an NSAID commonly used in topical analgesic products for 
muscle pain, might also be able to affect 5-HT3 and/or NMDA or non-NMDA glutamate 
receptors as part of its analgesic mechanism (ix) (9).  Diclofenac had no effect of 5-HT 
or AMPA (GluR selective agonist) mediated temporalis and masseter muscle nociceptor 
discharges, however, it significantly attenuated NMDA-evoked nociceptor discharges 
from this muscle (9).  Diclofenac appeared to exert a competitive antagonism of the NR, 
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as its inhibitory effects could be overcome by increasing the concentration of NMDA 
injected into the muscle.  Diclofenac also completely inhibited NMDA-induced 
mechanical sensitization of masseter muscle nociceptors (9).   
  
Figure 9:  A. The peristimulus 
histogram illustrates NMDA-
evoked afferent discharge.  B. 
The vertical bar chart compares 
the median (lines: interquartile 
range) relative cumulative 
discharge evoked by repeated 
injection of NMDA alone or when 
ketorolac (K0.5 = 0.5mM, K0.05 = 
0.05mM) or naproxen (N = 5mM) 
were added to the second 
injection of NMDA (n=5) *:p 
<0.05, Kruskal-Wallis One Way 
ANOVA on Ranks, Dunn’s post-
hoc test.  C.  The line and scatter 
plot shows mean (±SE) relative 
MT.  # p<0.05, two-way repeated 
measures ANOVA and Holm-
Sidak post hoc test. 
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Subsequent work was undertaken to determine whether the NR antagonism was 
a unique property of diclofenac, or if other NSAIDs might share this property (xii) (12).  
It was found that ketorolac, an injectable NSAID, also attenuates NMDA-evoked rat 
masseter muscle nociceptor discharges (Figure 9).  Ketorolac had no significant effect 
on masticatory muscle nociceptor discharge evoked by αβ-methylene ATP, AMPA, or 5-
HT, which suggests that it had no effect on the P2X3, GluR or 5-HT3 receptors (12).  In 
contrast, naproxen, another commonly used NSAID analgesic, had no effect on NMDA-
evoked nociceptor discharges (12).   It was suggested that internal structures of 
diclofenac and ketorolac, which resemble glutamate and NMDA, respectively, are 
responsible for the ability of these NSAIDs to block peripheral NRs (12).  This feature 
may add to the effectiveness of these compounds when used as topical analgesics, 
particularly for non-inflammatory pain conditions such as myofascial TMD. 
 
 
Role of glutamate in chronic masticatory muscle pain conditions 
 The extent to which changes in extracellular glutamate contribute to pain and 
sensitivity in the craniofacial region remains uncertain.  One of the most common 
chronic pain conditions that involve the masticatory muscles is myofascial TMD.  This 
condition is characterized by ongoing pain in the masseter and/or temporalis muscles, 
that is often exacerbated by activity, such as eating, speaking and yawning, and can be 
often be provoked by palpation of specific points of the affected muscle(s) (94).   To 
ascertain whether activation of peripheral NRs might contribute to muscle pain in this 
condition, 14 patients (10 female, 4 male) with myofascial TMD were recruited for a 
randomized double blind crossover study to compare the effect of injection of ketamine 
43 
 
(10 mM, 0.2 ml) and saline (0.2 ml) into the most painful point in the masseter muscle 
on ongoing and provoked pain (viii) (8).  The concentration of ketamine employed was 
based on results discussed previously, which indicated that a concentration of 10 mM 
ketamine significantly attenuated glutamate-evoked masseter muscle pain in healthy 
humans and nociceptor discharges in rats (5).  Patients were asked to rate their pain on 
a 0-10 numeric rating scale and were assessed for pressure pain threshold over the 
injection site just prior to and at regular intervals (10, 15, 60, 180 min, 24 hours) after 
injection of ketamine or saline.  A decrease in pain rating of 50% or more was 
considered clinically meaningful.   One hour after injection, 4 women, and at 3 hours 
(and 24 hours) 5 women of the 10, respectively, reported a more than 50% decline in 
their pain intensity.  This decrease in pain was maintained for 24 hours.  Unfortunately, 
two subjects reported a substantial increase in pain at various times after ketamine 
injection.  In contrast, none of the 4 men in the study reported a similar decrease 50% 
decrease in pain intensity after ketamine.  Injection of saline did not improve pain 
ratings in any of the subjects for more than 15 min post injection.  There was no overall 
effect of ketamine injections of pressure pain threshold (8).   
This study found that in half of the female myofascial TMD patients, ketamine 
injection into the most painful part of the muscle was effective in providing a clinically 
meaningful reduction of pain for up to 24 hours (8).  Unfortunately, this study was 
underpowered due to difficulties in recruiting patients given the invasive nature of the 
procedure, so it is unclear whether the results obtained would be applicable to a larger 
population.  In addition, patients who did not respond to a single site injection of 
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ketamine may have had more diffusely distributed pain in their muscles, making them 
less likely to respond to a single injection in a small area of the masseter muscle.  
Figure 10:  The result of intramuscular injection of ketamine into the most painful area 
of the masseter muscle of 10 female myofascial TMD patients on pain scores is show.  
One hour after injection, half the patients reported pain relief in excess of 50% (lower 
dotted line).  Interestingly, 6 reported a greater than 50% reduction in pain 24 hours 
after the single injection of ketamine. 
 
Finally, at the time the clinical trial of ketamine was conducted, it was unclear 
whether myofascial TMD patients have elevated masseter muscle interstitial glutamate 
concentrations.  To try to answer that latter question, a microdialysis study was 
performed on myofascial TMD patients (xi). 
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 Microdialysis probes were inserted into the masseter muscle of 13 (10 women, 3 
men) myofascial TMD patients and 10 (8 women, 2 men) age-matched healthy controls 
and used to measure baseline interstitial glutamate concentrations (xi) (11).  In TMD 
patients, the probe was inserted into the most painful spot in the muscle.  The median 
concentration of glutamate in the masseter muscle was significantly greater in TMD 
patients than in the health control subjects.  However, there was no significant 
relationship between glutamate concentration and pain intensity in TMD patients.   In 
women, interstitial concentrations of glutamate in TMD patients were about 4-7 times 
higher than those in healthy controls (Figure 11).  As discussed above, significant 
mechanical sensitization of muscle nociceptors has been demonstrated when interstitial 
glutamate concentrations in the masseter muscle are increased 2-3 times above their 
baseline (6).  Serum glutamate concentrations were similar in patients and healthy 
control subjects (Figure 11), suggesting that the increased glutamate concentration 
measured in the masseter muscle was a local phenomenon (11).   These findings 
support a potential role for glutamate in the mechanisms that result in muscle pain and 
sensitivity in myofascial TMD.  The lack of relationship between glutamate concentration 
and pain intensity suggests that many other factors are likely important in determining 
the nature of pain from the masticatory muscles in this chronic pain condition. 
Figure 11:  The bar graph 
shows the concentration of 
glutamate measured in the 
interstitial fluid of the masseter 
muscle and serum. 
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Summary and Conclusions 
The research presented in this thesis indicates that elevated interstitial glutamate 
acts on NRs to alter the response properties of craniofacial muscle nociceptors.  When 
interstitial concentrations of glutamate in the muscle are elevated within a “physiological 
range” (≤ 200 µM), the principal effect of NR activation was found to be mechanical 
sensitization of the muscle nociceptor.  However, when pharmacological doses of high 
concentration glutamate (0.1-1 M) are administered intramuscularly, these both evoke 
action potential discharge and sensitize the nociceptor, also through activation of the 
NR.  Injection of 1 M glutamate into the masseter muscle produces local interstitial 
concentrations of glutamate that exceed 100 mM but decline below 10 mM in less than 
10 minutes (100).   These concentrations are in the range of the concentrations of 
glutamate estimated to be contained within synaptic vesicles. It is thought that vesicular 
release of glutamate can occur from the endings of sensory nerve fibers, including 
those that innervate skeletal muscle (10, 101).  This suggests that local vesicular 
release of glutamate, such as may occur after depolarization of the peripheral ending of 
the afferent fiber, is better modelled by injection of a high concentration of glutamate 
into the muscle.  However, afferent fibers that innervate the masseter muscle also 
contain the neuropeptides calcitonin gene related peptide and substance P (10, 13).   
Interestingly, although these neuropeptides are released by injection of high 
concentration glutamate into the muscle, they do not appear to contribute to glutamate-
induced nociceptor mechanical sensitization (10).   It seems that some other factor of 
NR activation contributes to the prolonged mechanical sensitization that is seen when 
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high concentrations of glutamate are injected into the masticatory muscles.  One 
possibility is that since the NR is permeable to calcium, it is the elevated calcium levels 
within the nociceptor ending that, by activation of downstream cascade pathways, 
initiate and maintain glutamate-induced nociceptor mechanical.  This concept has not 
yet been subjected to scientific investigation. 
Results presented in this thesis indicate that the mechanical sensitivity of 
masticatory muscle nociceptors is modulated by the concentration of glutamate in the 
interstitium.  Specifically, increasing interstitial glutamate concentrations by ~300% (to 
~65 µM) after systemic administration of MSG resulted in a decrease in the mechanical 
threshold of masseter muscle nociceptors by ~25%, while decreasing interstitial 
glutamate concentrations by ~75% by intramuscular injection of botulinum neurotoxin A, 
resulted in ~20% increase in nociceptor mechanical threshold (6, 10).     As mentioned 
in the Introduction, glutamate concentration in the muscle and tendon has been shown 
to be increased in a number of chronic and acute muscle pain conditions, including 
myofascial temporomandibular disorders (11, 35-38).  This leads to the question of 
whether modulation of glutamate concentration might be a means to control pain in 
conditions such as temporomandibular disorders.  Glutamate transporters may play a 
significant role in the rapid clearance of glutamate from the muscle interstitial fluid.  The 
glutamate transporter 1 (GLT-1) also known as the excitatory amino acid transporter 2 
(EAAT2) has been reported to be expressed peripherally in tissues such as skeletal 
muscle and is thought to play an important role in clearance of glutamate (102, 103).  A 
number of inhibitors and activators are available that modulate the activity of glutamate 
transporters (104).   Kainic acid, and an analogue, dihydrokainic acid, have selectivity 
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for EAAT2, and dihydrokainic acid may be a useful probe to investigate the role of this 
transporter, as it is a poor activator of inotropic glutamate receptors, unlike kainic acid 
(104).   In addition, a number of highly potent and selective EAAT2 inhibitors have been 
recently synthesized (104). In research looking at the role of glutamate and glutamate 
receptor activation in the trigeminal ganglion, it was reported that TFB/TBOA, a potent 
non-selective inhibitor of EAAT1-3, increases ganglion neuron action potential 
discharge evoked by intraganglionic injection of glutamate (105).   Additional research is 
required to better understand the role of EAATs in the modulation of glutamate 
concentrations outside of the central nervous system.  Future work may look at the 
possibility of enhancing transporter function and/or altering dietary intake of foods that 
may inhibit transporter function, as treatments for chronic craniofacial muscle pain. 
  Vesicular glutamate transporters (VGlut), which are required for the uptake of 
glutamate into synaptic vesicles, have also been identified in skeletal muscle tissue 
(40).  Inhibitors include azo dyes such as Evans blue dye which binds with 90 nM 
affinity (106).  Additional inhibitors of VGluts are being developed, and based on the 
finding that botulinum neurotoxin A, which acts to inhibit vesicular release by cleaving 
the docking protein SNAP 25, has a pronounce effect on nociceptor mechanical 
sensitivity in muscle (10), these agents may also be effective analgesics for 
musculoskeletal pain conditions that are associated with elevated tissue glutamate 
concentrations.    
The non-steroidal anti-inflammatory drugs (NSAIDs) are extensively used as 
analgesics for pain conditions that involve the masticatory muscles (94).  Unfortunately, 
NSAIDs have the potential to cause serious side effects that include gastrointestinal 
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ulceration, as well as altered renal function and blood pressure control.   Application of 
topical NSAID containing creams and ointments offer the possibility directing therapy to 
the source of pain with lessened systemic exposure.   Limited evidence suggests that 
topical may be as effective as oral diclofenac for the treatment of myofascial TMD-
related masticatory muscle pain (94).   However, topical NSAIDs achieve local tissue 
concentrations that are substantially higher than those achieved by systemic 
administration.  The findings presented in this thesis indicate that at high concentration, 
both diclofenac and ketorolac have NR antagonist activity, and it is proposed that this 
effect enhances their analgesic effect when they are administered topically or injected 
locally.  It has been determined that ketorolac, at a concentration that has been shown 
to exert both NR antagonist activity and local anesthetic like effects, significantly 
reduced pain produced by injection of hypertonic saline into the masseter muscle of 
healthy women (12, 107).  It would be of interest to determine if lower concentrations of 
ketorolac or diclofenac are selective NR antagonists when injected into the human 
masseter muscle, as an unpublished pilot study conducted a few years ago suggested 
that ketorolac is very effective in reducing glutamate-evoked muscle pain in healthy 
subjects.  
It now appears that one of the reasons for a lack of effect of ketamine in this 
study may have been that women are less sensitive than men to the local effects of 
ketamine (108).  Despite this, the results of a clinical trial with ketamine were 
disappointing.  Does this mean that peripheral glutamate receptors are not a good 
target for the development of useful peripherally-acting analgesic agents? It is important 
to consider that only one small clinical trial has been completed with ketamine.  This, of 
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course, reflects an important limitation to studies of peripheral glutamate receptor 
function in humans, namely that there are very few glutamate receptor antagonists 
approved for use in human subjects, despite interest in the potential of these 
compounds for analgesia.  Of the drugs that are currently available for use in humans, 
all have been designed for actions in the central nervous system, including the NSAIDs 
diclofenac and ketorolac.  Indeed, one of the problems with using ketamine to 
investigate the role of peripheral NRs, is that the drug is rapidly cleared from skeletal 
muscle into the systemic circulation, and thus it is difficult in vivo to maintain for any 
length of time the elevated tissue concentrations that appear to be necessary to block 
peripheral NRs.   Indeed, some positive results have been reported for local ketamine 
analgesia when it is delivered topically in an ointment, a situation where sustained 
elevated concentrations of ketamine in the skin may be maintained.  Clearly, though, 
additional research that examines other NR receptor antagonists, particularly those with 
NR subunit selectivity, is required before the potential utility of peripherally-acting 
glutamate receptor antagonists for pain treatment will be well understood. 
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